The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols

Sarcoma

Volumn 5, Issue 1, 2001, Pages 9-15

  Beverly Raney, R ^a   Maurer, Harold M ^b   Anderson, James R ^c   Andrassy, Richard J ^a   Donaldson, Sarah S ^d   Qualman, Stephen J ^e   Wharam, Moody D ^f   Wiener, Eugene S ^g   Crist, William M ^h  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e NATIONWIDE CHILDREN S HOSPITAL   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^h University of Missouri   (United States)

Author keywords

Childhood adolescence; IRS V Protocol; Rhabdomyosarcoma; Undifferentiated sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; TOPOTECAN; VINCRISTINE;

ADULT; ARTICLE; BLADDER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; EYE; GRANULAR CELL TUMOR; HISTOLOGY; HUMAN; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RHABDOMYOSARCOMA; RISK ASSESSMENT; SURVIVAL RATE; UNITED STATES; VAGINA;

EID: 0035052555     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13577140120048890     Document Type: Article

References (33)

1. The Intergroup Rhabdomyosarcoma Study-I. A final report
2. The Intergroup Rhabdomyosarcoma Study-II
3. The Third Intergroup Rhabdomyosarcoma Study
4. A feasibility, toxicity, and efficacy study of ifosfamide, actinomycin D, and vincristine for the treatment of childhood rhabdomyosarcoma: A report of the Intergroup Rhabdomyosarcoma Study IV Pilot Study
5. Cyclophosphamide dose escalation in combination with vincristine and actinomycin D (VAC) in gross residual sarcoma: A pilot study without hematopoietic growth factor support evaluating toxicity and response
6. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study (IRS) IV Pilot Study
7. Preliminary results for patients with local/regional tumors treated on the Intergroup Rhabdomyosarcoma Study-IV (1991-97)
8. Pretreatment TNM staging of childhood rhabdomyosarcoma: A report of the Intergroup Rhabdomyosarcoma Study Group
9. Primary reexcision for patients with 'microscopic residual' tumor following initial excision of sarcomas of trunk and extremity sites
10. Surgical lessons from the Integroup Rhabdomyosarcoma Study (IRS) pertaining to extremity tumors
11. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergrup Rhabdomyosarcoma Studies I to III
12. Survival is improved in clinical group III children with complete response (CR) established by second-look operations in the Intergroup Rhabdomyosarcoma Study (IRS) III
13. What is optimal management for children or adolescents with localized paratesticular rhabdomyosarcoma? - Results of IRS-III and IRS-IV
14. Which patients with rhabdomyosarcoma (RMS) and microscopic residual tumor (Group II) fail therapy? A report from the Intergroup Rhabdomyosarcoma Study Group (IRSG)
15. Results from the Intergroup Rhabdomyosarcoma Study-IV randomized trial of hyperfractionated radiation in children with rhabdomyosarcoma
16. Results of treating localized cranial parameningeal sarcoma on Intergroup Rhabdomyosarcoma (RMS) Studies (IRS)-II through-IV, 1978-1997
17. Improved outcome for patients (pts) with embryonal (emb) histology (hist) but not alveolar hist rhabdomyosarcoma (RAMS): Results from Intergroup Rhabdomyosarcoma Study IV (IRS-IV)
18. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: An Intergroup Rhabdomyosarcoma Study (IRSG)
19. Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II; clinicopathologic correlations
20. Prognosis in children with rhabdomyosarcoma: A report of the Intergroup Rhabdomyosarcoma Studies I and II
21. Preservation of the bladder in patients with rhabdomyosarcoma
22. Molecular genetics and pathogenesis of rhabdomyosarcoma
23. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma
24. P-Glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma
25. Germ line mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
26. The Li-Fraumeni syndrome: From clinical epidemiology to molecular genetics
27. Second malignant neoplasms in children treated for rhabdomyosarcoma
28. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: An interim report
29. Second malignant neoplasms (SMN) in IRSG-IV: A preliminary report from the Intergroup Rhabdomyosarcoma Study Group (IRSG)
30. A Phase I study of irinotecan (CPT-11) in children with relapsed solid tumors
31. Prognostic significance of regional lymph node involvement in childhood extremity rhabdomyosarcoma
32. Lymphatic mapping with sentinel node biopsy in pediatric patients